For US Healthcare Providers Only

For US Healthcare Providers Only

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

TOP

IMPORTANT SAFETY INFORMATION

Indication

Makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history

Important Safety Information for Makena
(hydroxyprogesterone caproate injection)

  • Do not use Makena in women with any of the following conditions:

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

We acknowledge there may be some confusion in the healthcare community about the current status of Makena. At this time, it is important to know that Makena’s approval and product label remain unchanged. To learn more about current medical association guidelines, you can visit the American College of Obstetricians and Gynecologists and/or the Society for Maternal-Fetal Medicine website(s).

If you have any questions regarding your patients on or prescribed Makena, please contact Makena Care Connection® at 1-800-847-3418 (M–F, 8AM–8PM ET) or by emailing info@makenacareconnection.com.

©2019 AMAG Pharmaceuticals, Inc. All rights reserved. PP-MKN-US-00578 11/19